OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Neurodegeneration is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	397
Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer’s disease through disrupted regulated intramembrane proteolysis	238
Regulation of the hippocampal translatome by Apoer2-ICD release	228
LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome	216
Retraction Note: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5– implications for dementia with lewy bodies	209
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	200
Tau interactome and RNA binding proteins in neurodegenerative diseases	180
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	174
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	171
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	156
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	150
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	143
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	138
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	134
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	126
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	110
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	105
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	99
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	96
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	94
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	91
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	89
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	87
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	87
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	82

The role of NURR1 in metabolic abnormalities of Parkinson’s disease	81
Recombinant cathepsins B and L promote α-synuclein clearance and restore lysosomal function in human and murine models with α-synuclein pathology	79
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	78
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	76
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	74
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	74
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	73
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	72
In Memoriam of Edward H. Koo, MD 1954–2025	72
Combination therapy using GDNF and cell transplant in Parkinson’s disease	72
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	72
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	69
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	66
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	66
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	64
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	61
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	60
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	60
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	56
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	55
Using mass spectrometry to validate mouse models of tauopathy	55
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	54
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	53
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	53
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	53
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease	53
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	52